Context Therapeutics Inc.
For the period ended Sep 30, 2025. Filed Nov 5, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 5, 2025
CNTX$0.20+3.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations
| Three Months Ended September 30, | Nine Months Ended September 30, | |||
|---|---|---|---|---|
| 2025 | 2024 | 2025 | 2024 | |
| Operating expenses: | ||||
| Research and development | $8,722,104 | $16,825,198 | $20,015,639 | $20,182,960 |
| General and administrative | 1,888,376 | 1,876,230 | 5,882,346 | 5,430,518 |
| Loss from operations | (10,610,480) | (18,701,428) | (25,897,985) | (25,613,478) |
| Interest income | 833,772 | 1,243,687 | 2,696,061 | 2,236,188 |
| Other income (expense) | 83,471 | (2,152) | 103,916 | (4,906) |
| Net loss | $(9,693,237) | $(17,459,893) | $(23,098,008) | $(23,382,196) |
| Net loss per common share, basic and diluted | $(0.10) | $(0.22) | $(0.24) | $(0.46) |
| Weighted average shares outstanding, basic and diluted | 95,185,187 | 80,481,053 | 95,186,346 | 50,578,115 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.